Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
Schubert ML, Dietrich S, Stilgenbauer S, Schmitt A, Pavel P, Kunz A, Bondong A, Wegner M, Stadtherr P, Jung S, Ho AD, Müller-Tidow C, Schmitt M, Dreger P.
Schubert ML, et al.
Biol Blood Marrow Transplant. 2020 Sep;26(9):1575-1580. doi: 10.1016/j.bbmt.2020.04.025. Epub 2020 May 15.
Biol Blood Marrow Transplant. 2020.
PMID: 32422254
Free article.
CAR therapy consisted either of a third-generation CAR (HD-CAR-1) or of commercially manufactured axicabtagene ciloleucel (axi-cel; Gilead, Santa Monica, U.S.). Altogether, 10 CAR T cell dosings using recipient leukapheresis products were performed in 8 patients: 4 patient …
CAR therapy consisted either of a third-generation CAR (HD-CAR-1) or of commercially manufactured axicabtagene ciloleucel (axi-cel; Gilead, …